Cannabis-based medicinal products (Sativex)

Do Not Prescribe (DNP), Red, Green - after consultant/specialist initiation
Decision Date:
December 2019


Cannabis - based products listed in NICE NG144 include:

  • Nabilone
  • THC:CBD (combination of delta-9-tetrahydrocannabinol with cannabidiol - Sativex)
  • Dronabinol
  • THC (delta-9-tetrahydrocannabinol)
  • Cannabidiol (Epidyolex) with clobazam

JAPC classification for each NICE indication:


GREEN after consultant/specialist initiation:


  • NICE NG144: Seizures associated with Lennox-Gastaut syndrome & Dravet syndrome.  (See also TA614 & TA615 below).  (NHSE commissioned).
  • NICE TA614 - Cannabidiol (Epidyolex) with clobazam for treating seizures associated with Dravet syndrome.  (NHSE commissioned).  (Decision date - January 2020).
  • NICE TA615 - Cannabidiol (Epidyolox) with clobazam for treating seizures associated with Lennox-Gastaut syndrome.  (NHSE commissioned) (Decision date - January 2020).
  • NICE TA873 - Cannabidiol for treating seizures caused by tuberous sclerosis complex. (NHSE commissioned) (Decision date - April 2023)

Do Not Prescribe (DNP):

  • NICE NG144 - intractable nausea and vomiting.  (NHSE commissioned).
  • NICE NG144 - chronic pain.  (NHSE commissioned).
  • NICE NG144 - severe treatment - resistant epilepsy.  (NHSE commissioned).


Red Drug Classifications

  • 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app